Trial · NCT07907666
Ropivacaine Alone Versus Ropivacaine Plus Lidocaine With or Without Epinephrine for Supraclavicular Brachial Plexus Block in Upper Limb Orthopedic Surgery
NCT07907666, Phase 4, Completed, Instituto Mexicano del Seguro Social
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ropivacaine Alone Versus Ropivacaine Plus Lidocaine With or Without Epinephrine for Supraclavicular Brachial Plexus Block in Upper Limb Orthopedic Surgery. Trials, record NCT07907666. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907666
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ropivacaine Alone Versus Ropivacaine Plus Lidocaine With or Without Epinephrine for Supraclavicular Brachial Plexus Block in Upper Limb Orthopedic Surgery
- NCT number
- NCT07907666
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 138 participants, actual
- Lead sponsor
- Instituto Mexicano del Seguro Social
- Conditions
- Postoperative Pain, Upper Extremity Fracture, Anesthesia, Conduction
- Interventions
- ropivacaine, lidocaine, lidocaine with epinephrine
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Postoperative Pain Intensity at 6 Hours | 6 hours after the end of surgery | Pain intensity measured with the 11-point Numeric Rating Scale (NRS), from 0 (no pain) to 10 (worst imaginable pain), compared among the three groups. |
| Secondary | Postoperative Pain Intensity at 0 and 12 Hours | Immediately after the end of surgery (0 hours) and 12 hours after the end of surgery | Pain intensity measured with the 11-point Numeric Rating Scale (NRS), from 0 (no pain) to 10 (worst imaginable pain). |
| Secondary | Number of Participants Requiring Rescue Analgesia (Duration of Analgesia) | At 0, 6 and 12 hours after the end of surgery | Number of participants who received rescue analgesia at each assessment; participants without rescue at 6 hours were considered to have an analgesia duration of at least 6 hours. |
| Secondary | Rescue Analgesic Consumption by Drug Type | Up to 12 hours after the end of surgery | Number of participants receiving each rescue analgesic (acetaminophen, ketorolac, diclofenac, lysine clonixinate or opioids) and dose administered. |
| Secondary | Number of Participants Receiving Postoperative Opioids | Up to 12 hours after the end of surgery | Number of participants who received at least one opioid |
| Secondary | Upper Limb Motor Block (Modified Bromage Scale) | At 0, 6 and 12 hours after the end of surgery | Motor block of the blocked upper limb graded with the modified Bromage scale: 0 = full movement, 1 = decreased strength, 2 = partial movement, 3 = complete motor block. |
| Secondary | Number of Participants With Block-Related Adverse Events | Up to 12 hours after the end of surgery | Nausea, vomiting, paresthesia, puncture-site hematoma, Horner syndrome, dyspnea or phrenic nerve block, and local anesthetic systemic toxicity. |
| Other | Block Onset Time | Intraoperative, from local anesthetic injection to onset of anesthesia | Time in minutes from local anesthetic administration to onset of anesthesia, marked on the monitor and recorded in the anesthesia record by the attending anesthesiologist. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907666
GET https://conductscience.org/api/trials/v1/NCT07907666/registered